NCT05764395 2026-04-27Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 InhibitorsVanderbilt-Ingram Cancer CenterPhase 2 Active not recruiting7 enrolled